Robert Parnes, MD
Retina Specialist · Hagerstown, MDNPI 1407824360
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $5,202 of the $7,407 with a category attached, or 70.2%. US Retina LLC accounts for 70.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $2,495 and has fallen 95.6% since, to $110 in 2024.
Across 29 payments — averaging $255.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$5K
- Carl Zeiss Meditec, Inc.$2K
- Genentech USA, Inc.$229
- Regeneron Healthcare Solutions, Inc.$145
- Bausch & Lomb Americas Inc.$52
- AbbVie$47
- plus $106 from 3 others
Across 15 payments — averaging $15,054 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eyepoint US, Inc.$141K
- Hexal AG$85K
What the payments were for
- Consulting fees$1,62522%
- Food & beverage$5417%
- Gifts$391%
- Ownership interest$5,20270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $5,202 |
| Carl Zeiss Meditec, Inc. | 1 | $1,625 |
| Genentech USA, Inc. | 5 | $229 |
| Regeneron Healthcare Solutions, Inc. | 6 | $145 |
| Bausch & Lomb Americas Inc. | 3 | $52 |
| AbbVie | 3 | $47 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Novartis | 2 | $35 |
| Apellis Pharmaceuticals, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$150
How this compares
$7,407 in reported general payments places this provider in the 80th percentile of 47 retina specialist providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 29 | $9,880 |
| Bromfenac Sodium | 37 | $8,023 |
| Prednisolone Acetate | 122 | $4,301 |
| Brimonidine Tartrate | 12 | $2,623 |
| MoxifloxacinMoxifloxacin Hcl | 90 | $1,836 |
| Difluprednate | 16 | $1,275 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $549 |
| ErythromycinErythromycin Base | 58 | $522 |
| Atropine Sulfate | 12 | $445 |
| Ketorolac Tromethamine | 24 | $304 |
| Dorzolamide Hcl | 22 | $292 |
| Latanoprost | 22 | $186 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Hagerstown
- Adam GerstenblithHagerstown$107K
- Adam WenickHagerstown$5K
- Erwin PuenteHagerstown$4K
- Rohit LakhanpalOwings Mills$168K
- Brian DoChevy Chase$116K
- Aziz KhanifarSilver Spring$83K
- Michael ElmanBaltimore$27K
- Reginald SandersGreenbelt$24K
- Sidney SchechetBaltimore$23K
- Mohsin AliGreenbelt$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.